Tempest Therapeutics Stock Fundamentals
| TPST Stock | USD 0.91 0.02 2.25% |
Tempest Therapeutics fundamentals help investors to digest information that contributes to Tempest Therapeutics' financial success or failures. It also enables traders to predict the movement of Tempest Stock. The fundamental analysis module provides a way to measure Tempest Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tempest Therapeutics stock.
At this time, Tempest Therapeutics' Interest Expense is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 15.4 M in 2024, whereas EBIT is likely to drop (30.6 M) in 2024. Tempest | Select Account or Indicator |
Tempest Therapeutics Company Return On Equity Analysis
Tempest Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Tempest Therapeutics Return On Equity | -2.89 |
Most of Tempest Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tempest Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Tempest Common Stock Total Equity
Common Stock Total Equity |
|
Based on the latest financial disclosure, Tempest Therapeutics has a Return On Equity of -2.8926. This is 87.93% lower than that of the Biotechnology sector and 92.07% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Tempest Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Tempest Therapeutics's current stock value. Our valuation model uses many indicators to compare Tempest Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Tempest Therapeutics competition to find correlations between indicators driving Tempest Therapeutics's intrinsic value. More Info.Tempest Therapeutics is rated below average in return on equity category among its peers. It is rated fourth in return on asset category among its peers . At this time, Tempest Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Tempest Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Tempest Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tempest Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tempest Therapeutics could also be used in its relative valuation, which is a method of valuing Tempest Therapeutics by comparing valuation metrics of similar companies.Tempest Therapeutics is currently under evaluation in return on equity category among its peers.
Tempest Fundamentals
| Return On Equity | -2.89 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 34.62 M | ||||
| Shares Outstanding | 43.64 M | ||||
| Shares Owned By Insiders | 0.24 % | ||||
| Shares Owned By Institutions | 23.02 % | ||||
| Number Of Shares Shorted | 2.64 M | ||||
| Price To Earning | 0.23 X | ||||
| Price To Book | 3.40 X | ||||
| EBITDA | (28.78 M) | ||||
| Net Income | (29.49 M) | ||||
| Cash And Equivalents | 51.62 M | ||||
| Cash Per Share | 4.95 X | ||||
| Total Debt | 20.66 M | ||||
| Debt To Equity | 0.49 % | ||||
| Current Ratio | 3.05 X | ||||
| Book Value Per Share | 1.21 X | ||||
| Cash Flow From Operations | (27.36 M) | ||||
| Short Ratio | 0.39 X | ||||
| Earnings Per Share | (1.53) X | ||||
| Target Price | 18.75 | ||||
| Number Of Employees | 17 | ||||
| Beta | -2.78 | ||||
| Market Capitalization | 39 M | ||||
| Total Asset | 51.6 M | ||||
| Retained Earnings | (165.26 M) | ||||
| Working Capital | 30.95 M | ||||
| Net Asset | 51.6 M |
About Tempest Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tempest Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tempest Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tempest Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 300.6 K | 267.2 K | |
| Cost Of Revenue | 381 K | 361.9 K | |
| Stock Based Compensation To Revenue | 21.03 | 21.71 | |
| Sales General And Administrative To Revenue | 84.64 | 71.67 | |
| Research And Ddevelopement To Revenue | 44.32 | 30.23 | |
| Capex To Revenue | 0.02 | 0.01 | |
| Revenue Per Share | 227.29 | 238.66 | |
| Ebit Per Revenue | (79.85) | (83.84) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.